XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Operations (USD $)
 3 Months Ended 12 Months Ended
Mar. 31, 2012
Mar. 31, 2012
Costs and expenses:    
Non-cash stock expense associated with in-licensing agreement $ 16,578,000 $ 16,875,000
Other research and development 163,353 193,636
Total research and development 16,741,353 17,068,636
General and administrative:    
Non-cash compensation 188,509 275,003
Other general and administrative 455,492 923,689
Total general and administrative 644,001 1,198,692
Total costs and expenses 17,385,354 18,267,328
Operating loss (17,385,354) (18,267,328)
Other (income) expense:    
Interest income (3,668) (3,668)
Interest expense 220,149 227,246
Change in fair value of non-current notes payable (205,297) (205,297)
Total other (income) expense 11,184 18,281
Net loss (17,396,538) (18,285,609)
Net loss attributable to non-controlling interest (7,140,448) (7,176,445)
Net loss attributable to TG Therapeutics, Inc. and subsidiaries $ (10,256,090) $ (11,109,164)
Basic and diluted net loss per common share (in dollars per share) $ (2.03)  
Weighted average shares used in computing basic and diluted net loss per common share (in shares) 5,061,399